| Extracorporeal removal of endotoxin: the polymyxin B-immobilized fiber cartridge. | |
| | |
MedLine Citation:
|
PMID: 20519897 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Endotoxin, which consists of lipopolysaccharide (LPS), is an outer membrane component of the Gram-negative bacterial cell wall. Endotoxin in the blood stream from an infectious focus or through translocation from the gut plays an important role in the pathogenesis of severe sepsis and septic shock. It binds to monocytes and macrophages, activating them to trigger the production of a variety of mediators. These mediators injure endothelial cells and induce microcirculatory dysfunction. This leads to subsequent organ dysfunction and multiorgan failure. The neutralization or elimination of endotoxin in the blood is an enticing approach for treating severe sepsis and septic shock. Selective adsorbent therapy targeting blood endotoxin has been clinically applied for more than 15 years, mainly in Japan and more recently in Italy and other countries. Toraymyxin(TM) (PMX;Toray, Tokyo, Japan) is a selective blood endotoxin removal cartridge. PMX is composed of polymyxin B (PL-B) covalently bonded to polystyrene-derivative fibers. It is well known that PL-B binds endotoxin and has bactericidal activity. PL-B has a strong affinity to endotoxin and is able to bind the lipid A portion of endotoxin through ionic and hydrophobic interactions. Intravenous injection of PL-B has significant nephrotoxic and neurotoxic effects. However, covalently immobilized PL-B on the adsorbents of PMX do not leak out into the blood stream, thus allowing the clinical application without the known toxic effects of PL-B. Within each cartridge, an adsorbent structure made of PL-B-fixed fabrics is included. Blood flow direction is well controlled by adopting a radial flow system. PMX treatment occurs by hemoperfusion at a blood flow rate of about 80-120 ml/min. Heparinis preferably used as an anticoagulant. In Japan, PMX has been clinically used since 1994under the national health insurance system. It is estimated that over 80,000 patients have received PMX treatment in Japan. Not only has PMX been clinically used safely in Japan, but also in other countries. |
| | |
Authors:
|
Tohru Tani; Hisataka Shoji; Gualtiero Guadagni; Angelo Perego |
Related Documents
:
|
3234617 - Induction of anacidity restores gastric aminopyrine clearance in canine hemorrhagic shock. 1720367 - Resuscitation fluids for the treatment of hemorrhagic shock in dogs: effects on myocard... 12188497 - Osteonecrosis of the humeral head after extracorporeal shock-wave lithotripsy. 7879977 - Blood coagulopathy in dogs with shock induced by injection of heartworm extract. 16984577 - Altered skin blood perfusion in areas with non blanchable erythema: an explorative study. 11467337 - Oxygen effects on glucose measurements with a reference analyzer and three handheld met... |
Publication Detail:
|
Type: Journal Article Date: 2010-06-01 |
Journal Detail:
|
Title: Contributions to nephrology Volume: 167 ISSN: 1662-2782 ISO Abbreviation: Contrib Nephrol Publication Date: 2010 |
Date Detail:
|
Created Date: 2010-06-03 Completed Date: 2010-07-07 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7513582 Medline TA: Contrib Nephrol Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 35-44 Citation Subset: IM |
Copyright Information:
|
Copyright 2010 S. Karger AG, Basel. |
Affiliation:
|
Department of Surgery, Shiga University of Medical Science, Otsu City, Shiga, 520-2121, Japan. tan@belle.shiga-med.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Bacterial Infections
/
blood,
drug therapy Endotoxins / antagonists & inhibitors Hemoperfusion / methods Humans Lipopolysaccharides / isolation & purification*, toxicity Polymyxin B / therapeutic use Polypropylenes / therapeutic use Polystyrenes / therapeutic use Shock, Septic / blood*, drug therapy Vaccines / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Endotoxins; 0/Lipopolysaccharides; 0/Polypropylenes; 0/Polystyrenes; 0/Vaccines; 1404-26-8/Polymyxin B |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Rationale of Extracorporeal Removal of Endotoxin in Sepsis: Theory, Timing and Technique.
Next Document: Mechanisms of Polymyxin B Endotoxin Removal from Extracorporeal Blood Flow: Molecular Interactions.